Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study.

doi:10.1186/s12933-026-03304-y

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study.

Cardiovascular diabetology - 22 Jul 2026

Li Jiang, Li Jie, Xu Xiaoqin, Wang Ningjian, Lu Yingli, Wang Bin

Abstract excerpt

BACKGROUND: Glucagon-like peptide-1 receptor (GLP1R) agonists and dual glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor (GIPR/GLP1R) agonists are established treatments for diabetes and obesity, but their potential effects on biological aging remain uncertain. METHODS: In this drug target Mendelian randomization study, we assessed the associations of genetically proxied...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Frailty

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucagon-Like Peptide-1 Receptor

Share to Glycated Hemoglobin

Share to Hypoglycemic Agents

Share to Longevity

Share to Pharmacogenomic Variants

Share to Telomere Homeostasis

Source

Open in PubMed Open full text

Identifiers

PMID: 42642762
DOI: 10.1186/s12933-026-03304-y
PMCID: PMC13504813

Genes

GIPR
GLP1R

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.